Public Health

Health Products Regulatory Authority (HPRA) safety notices

Click here for details.

Epidemiological Update Measles - 7 August 2019

Since the PAHO/WHO Epidemiological Update on Measles published on 18 June, there has been a 70% increase in the total number of confirmed cases of measles reported, with 7 countries and territories reporting additional confirmed cases. » read more

Protocol for Reporting and Management of cases of Creutzfeldt Jakob Disease (CJD) and other Transmissible Spongiform Encephalopathies (TSEs)

The guideline document Protocol for Reporting and Management of cases of Creutzfeldt Jakob Disease (CJD) and other Transmissible Spongiform Encephalopathies (TSEs) or of a person at increased risk of a TSE is now available on the HPSC website. » read more

Revised Mental Health Commission Statutory forms

The Mental Health Commission has revised all of its Statutory forms. Forms 1 to 5 are the ones that are relevant to us in our roles as GPs referring patients for involuntary committal to hospital. » read more

Chikungunya Iceland ex Alicante Spain

Iceland have reported three confirmed cases of autochthonous Chikungunya infections from Alicante, Spain, that have been identified in Iceland. Additionally one person is under investigation in Norway. » read more

Breast Implant Associated Anaplastic Large Cell Lymphoma (BIA-ALCL)

BIA-ALCL is a rare but important disease affecting individuals with breast implants. » read more

Use of Xeljanz (tofacitinib) restricted while European Medicines Agency (EMA) review regarding the risk of pulmonary embolism is ongoing

The HPRA would like to inform you that the European Medicines Agency's (EMA) Pharmacovigilance Risk Assessment Committee (PRAC) have initiated a review (Article 20 Referral) of Xeljanz (tofacitinib) following evaluation of data from an ongoing clinical trial in which an increased risk of pulmonary embolism (PE) and overall mortality was observed in patients using the tofacitinib 10mg twice daily dose. » read more

Direct Healthcare Professional Communication

Systemic and inhaled quinolone and fluoroquinolone antibiotics - risk of disabling, long lasting and potential irreversible side effects and restrictions on use. » read more

HSE Public Health Alert: Increase in measles notifications Ireland weeks

There has been an increase in the number of measles cases reported to the HSE since the beginning of the year. This email is to inform you of the risk of cases being seen in other parts of the country, even outside the main outbreak areas (East and Northwest) » read more

Treatment options for hypoglycaemia management

The introduction of the sugar tax in 2017 and the reformulation of some commonly used hypoglycaemia treatment options have highlighted the issue of healthcare professional recommendations for the home treatment of hypoglycaemia. » read more

Measles in Tunisia

WHO update on measles in Tunisia alert 1 » read more

Email:, Tel: 01 6763705, Fax: 01 6765850
Learn More To give you the best possible experience, our sites use cookies. Continuing with cookies enabled means you're OK with this. Click Learn More for more information about our cookies, and how to disable them. ×